FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308587733> ?p ?o ?g. }

• W4308587733 abstract "Anti‑programmed cell death protein‑1 (PD‑1)/programmed cell death 1 ligand 1 (PD‑L1) antibodies have been widely used in cancers. The present study aimed to evaluate the efficacy and safety of PD‑1/PD‑L1 inhibitors in human cancers. Studies were searched from Cochrane Library, PubMed and Embase databases. Randomized controlled trials (RCTs) that investigated adjuvant therapy with anti‑PD‑1/PD‑L1 agents in solid cancers were eligible for inclusion. As the primary focus of the meta‑analysis, clinical outcome measures including overall survival (OS), disease‑free survival (DFS), and adverse events (AEs) were analyzed by Stata 15.0 software. A total of six RCTs (n=4,436) met the inclusion criteria. The DFS [hazard ratio (HR)=0.71; 95% confidence interval (CI): 0.63‑0.78; P<0.001] and OS (HR=0.66, 95% CI: 0.46‑0.86, P<0.001) of patients were significantly prolonged by adjuvant immunotherapy. Subgroup analysis indicated that significantly improved DFS was observed in patients treated with different anti‑PD‑1/PD‑L1 drugs (nivolumab, pembrolizumab, or atezolizumab), as well as in those with different tumors (melanoma, urothelial carcinoma, esophageal or gastroesophageal junction cancer, or renal cell carcinoma), and PD‑L1 status [negative (<1%) or positive (≥1%)]. However, PD‑1/PD‑L1 inhibitors was associated with increased ≥ grade 3 treatment‑related AEs (odds ratio=1.63; 95% CI: 1.20‑2.21; P=0.002). The available evidence suggests that adjuvant therapy with PD‑1/PD‑L1 inhibitors provided more survival benefit than placebo for patients with cancer, with increased grade 3 or higher AEs. Prospero registration no. CRD42021290654." @default.
• W4308587733 created "2022-11-12" @default.
• W4308587733 creator A5012324763 @default.
• W4308587733 creator A5041790462 @default.
• W4308587733 creator A5048493212 @default.
• W4308587733 creator A5071909292 @default.
• W4308587733 creator A5077176713 @default.
• W4308587733 creator A5079840330 @default.
• W4308587733 date "2022-11-08" @default.
• W4308587733 modified "2023-09-28" @default.
• W4308587733 title "Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer" @default.
• W4308587733 cites W1984294807 @default.
• W4308587733 cites W2048300023 @default.
• W4308587733 cites W2055290659 @default.
• W4308587733 cites W2060953438 @default.
• W4308587733 cites W2070825440 @default.
• W4308587733 cites W2094973862 @default.
• W4308587733 cites W2098923148 @default.
• W4308587733 cites W2160834915 @default.
• W4308587733 cites W2177405394 @default.
• W4308587733 cites W2321112275 @default.
• W4308587733 cites W2560367415 @default.
• W4308587733 cites W2588681363 @default.
• W4308587733 cites W2790907228 @default.
• W4308587733 cites W2794577178 @default.
• W4308587733 cites W2797309423 @default.
• W4308587733 cites W2889669338 @default.
• W4308587733 cites W2970819265 @default.
• W4308587733 cites W3008725477 @default.
• W4308587733 cites W3015816649 @default.
• W4308587733 cites W3024460671 @default.
• W4308587733 cites W3028977143 @default.
• W4308587733 cites W3030308619 @default.
• W4308587733 cites W3046869151 @default.
• W4308587733 cites W3061157080 @default.
• W4308587733 cites W3087210493 @default.
• W4308587733 cites W3087697977 @default.
• W4308587733 cites W3138703636 @default.
• W4308587733 cites W3148827278 @default.
• W4308587733 cites W3153228158 @default.
• W4308587733 cites W3163995648 @default.
• W4308587733 cites W3196207248 @default.
• W4308587733 cites W3199241644 @default.
• W4308587733 doi "https://doi.org/10.3892/etm.2022.11685" @default.
• W4308587733 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36561965" @default.
• W4308587733 hasPublicationYear "2022" @default.
• W4308587733 type Work @default.
• W4308587733 citedByCount "0" @default.
• W4308587733 crossrefType "journal-article" @default.
• W4308587733 hasAuthorship W4308587733A5012324763 @default.
• W4308587733 hasAuthorship W4308587733A5041790462 @default.
• W4308587733 hasAuthorship W4308587733A5048493212 @default.
• W4308587733 hasAuthorship W4308587733A5071909292 @default.
• W4308587733 hasAuthorship W4308587733A5077176713 @default.
• W4308587733 hasAuthorship W4308587733A5079840330 @default.
• W4308587733 hasBestOaLocation W43085877331 @default.
• W4308587733 hasConcept C121608353 @default.
• W4308587733 hasConcept C126322002 @default.
• W4308587733 hasConcept C143998085 @default.
• W4308587733 hasConcept C156957248 @default.
• W4308587733 hasConcept C197934379 @default.
• W4308587733 hasConcept C207103383 @default.
• W4308587733 hasConcept C2775949291 @default.
• W4308587733 hasConcept C2777472916 @default.
• W4308587733 hasConcept C2777701055 @default.
• W4308587733 hasConcept C2777863537 @default.
• W4308587733 hasConcept C2777982462 @default.
• W4308587733 hasConcept C2780030458 @default.
• W4308587733 hasConcept C2780057760 @default.
• W4308587733 hasConcept C44249647 @default.
• W4308587733 hasConcept C71924100 @default.
• W4308587733 hasConcept C90924648 @default.
• W4308587733 hasConceptScore W4308587733C121608353 @default.
• W4308587733 hasConceptScore W4308587733C126322002 @default.
• W4308587733 hasConceptScore W4308587733C143998085 @default.
• W4308587733 hasConceptScore W4308587733C156957248 @default.
• W4308587733 hasConceptScore W4308587733C197934379 @default.
• W4308587733 hasConceptScore W4308587733C207103383 @default.
• W4308587733 hasConceptScore W4308587733C2775949291 @default.
• W4308587733 hasConceptScore W4308587733C2777472916 @default.
• W4308587733 hasConceptScore W4308587733C2777701055 @default.
• W4308587733 hasConceptScore W4308587733C2777863537 @default.
• W4308587733 hasConceptScore W4308587733C2777982462 @default.
• W4308587733 hasConceptScore W4308587733C2780030458 @default.
• W4308587733 hasConceptScore W4308587733C2780057760 @default.
• W4308587733 hasConceptScore W4308587733C44249647 @default.
• W4308587733 hasConceptScore W4308587733C71924100 @default.
• W4308587733 hasConceptScore W4308587733C90924648 @default.
• W4308587733 hasIssue "6" @default.
• W4308587733 hasLocation W43085877331 @default.
• W4308587733 hasLocation W43085877332 @default.
• W4308587733 hasLocation W43085877333 @default.
• W4308587733 hasOpenAccess W4308587733 @default.
• W4308587733 hasPrimaryLocation W43085877331 @default.
• W4308587733 hasRelatedWork W2766583070 @default.
• W4308587733 hasRelatedWork W2785808209 @default.
• W4308587733 hasRelatedWork W2802256694 @default.
• W4308587733 hasRelatedWork W2957427793 @default.
• W4308587733 hasRelatedWork W2969038597 @default.
• W4308587733 hasRelatedWork W3000961096 @default.

• next